摘要
目的探讨瑞舒伐他汀对代谢综合征(MS)病人超敏C反应蛋白(hs-CRP)、白细胞介素-18(IL-18)及胰岛素抵抗(IR)的影响。方法将40例MS病人随机分为治疗组和对照组。两组均给予降压治疗,同时治疗组给予瑞舒伐他汀10 mg/d治疗。两组治疗6周后检测低密度脂蛋白、高密度脂蛋白、hs-CRPI、L-18、空腹血糖(FBG)、空腹胰岛素水平,计算IR指数。结果治疗组治疗前后各指标比较差异均有显著性(t=4.20~21.19,P〈0.05);对照组治疗前后hs-CRP、FBG比较差异有显著性(t=5.53、9.02,P〈0.05),余指标治疗前后比较差异无显著性(P〉0.05)。两组治疗前后各指标的差值比较差异均有显著性(t=17.28,t′=4.90~20.85,P〈0.05)。结论瑞舒伐他汀可降低MS病人的hs-CRPI、L-18的水平,并改善IR。
Objective To study the effect of rosuvastatin on plasma level of interleukin-18(IL-18),high sensitivity C-reactive protein(hs-CRP),fasting blood glucose(FBG) and fasting insulin(FINS),as well as insulin resistance(IR) in patients with metabolic syndrome(MS).Methods Forty patients with MS were equally randomized to two groups: group A and group B.Patients in both groups were given antihypertensive therapy,at the same time,rosuvastatin was given to those in Group A with a dose of 10 mg,once a day.Plasma levels of low-density lipoprotein cholesterol,high-density lipoprotein cholesterol hs-CRP,IL-18,FBG and FINS were detected after six weeks of medication.IR was calculated.All examined items before and after six weeks treatment was analyzed.Results In comparison between before and after therapy,there were significant differences among allitems in group A(t=4.20-21.19,P0.05);in group B,only differences between hs-CRP and FBG were significant(t=5.53,9.02;P0.05).The differences between two groups in the differentials of detected items before and after treatment were significant(t=17.28,t′=4.90-20.85;P0.05).Conclusion Rosuvastatin can lower plasma level of hs-CRP and IL-18,as well as improve IR.
出处
《青岛大学医学院学报》
CAS
2011年第3期230-231,234,共3页
Acta Academiae Medicinae Qingdao Universitatis